- Company
- Keytruda annual sales top the market for the first time
- by Chon, Seung-Hyun Feb 24, 2021 06:02am
- An immunotherapy Keytruda has topped the South Korean pharmaceutical market for the first time. Its outstanding effect confirmed in treating various cancer types have generated sales profit to dominate the market. Anticancer treatment Tagrisso and immunotherapy Humira surpassed the annual sales of 100 billion won. A pneumococcal pneumonia vaccin
- Policy
- IMDs for Champix are being commercialized
- by Lee, Tak-Sun Feb 24, 2021 06:02am
- IMDs of domestic pharmaceutical companies that challenge Champix (Varenicline Tartrate, Pfizer) are attracting attention. This is because film-type formulations with enhanced convenience and SR formulations are promoting commercialization. Although generic products have already been released, demand for IMDs is expected to remain high. Ac
- Company
- Market sales of Saxenda & Qsymia are the highest ever
- by An, Kyung-Jin Feb 23, 2021 06:11am
- Despite COVID-19 incident last year, the domestic obesity treatment market set a new record. the market sales of Qsymia and Saxenda, which is known for injectables to lose weight, expanded to the highest level ever. According to IQVIA on the 23rd, the domestic market for obesity treatments last year was &8361;143 billion. It has achieved the l
- Company
- Gilead on its way to introduce HCV drug Epclusa in Korea
- by Eo, Yun-Ho Feb 23, 2021 06:11am
- Gilead is finally showcasing another pipeline for hepatitis C virus infection. The pharmaceutical industry source reported Gilead Science Korea has submitted an application for the South Korean health authority’s approval on a pan-genotype hepatitis C virus (HCV) infection treatment Epclusa (sofosbuvir/velpatasvir) to be used on an adul
- Company
- Competition between Soliris & Enspryng is predicted in Korea
- by Eo, Yun-Ho Feb 23, 2021 06:11am
- Competition between two expensive drugs is expected in the field of Neuromyelitis Optica Spectrum Disorder Aggravate (NMOSD) According to related industries, Roche's Enspryng (Satralizumab) is in the process of domestic approval, while Handok's Soliris (Eculizumab) recently added an indication for optic neuromyelitis. Soliris has been u
- Policy
- Antidiabetic drug GLP-1 RA to be recommended for NASH
- by Lee, in-bok Feb 23, 2021 06:11am
- The use of antidiabetic drug is to be expanded in treating non-alcoholic steatohepatitis (NASH) as the Korean Association for the Study of the Liver (KASL) gave a priority recommendation on prescription of pioglitazone. The prospective prescription strategy is likely to see a significant change as a glucagon-like peptide 1 receptor agonist (
- Policy
- Weighted average price of α-GPC, ₩512
- by Lee, Hye-Kyung Feb 22, 2021 06:18am
- The weighted average price of Choline alfoscerate 0.4g, which was the subject of reevaluation of the adequacy of benefits last year, decreased 0.2% from the previous year to &8361;512. The weighted average price of Vitis vinifera 50mg. and Avocado-Soya unsaponifiables 0.3g, which are undergoing re-evaluation this year, decreased by 1.7% and
- Company
- Dupixent to treat pediatric patients with atopic dermatitis
- by Eo, Yun-Ho Feb 22, 2021 06:17am
- The use of atopic dermatitis and asthma treatment Dupixent (dupilumab) could be expanding also in South Korea to be administered to children. A pharmaceutical industry source reported Sanofi Genzyme has submitted an indication expansion application last year on Dupixent to be indicated for a ‘treatment in pediatric patients aged six th
- InterView
- Genexine Licenses out immuno-cancer Drug Technology
- by Kim, Jin-Gu Feb 22, 2021 06:17am
- Genexine announced on the 18th that it has signed a technology transfer contract worth &8361;1.2 trillion with KG BIO, a subsidiary of Indonesian pharmaceutical company Kalbe Farma, for GX-17, an immune anticancer drug candidate. KG BIO is a joint venture established in 2016 by Kalbe Farma, the largest pharmaceutical company in Southeast
- Policy
- Central Committee conflicted over Rekirona limits use
- by Lee, Tak-Sun Feb 22, 2021 06:17am
- Apparently, the Central Pharmaceutical Affairs Deliberation Committee has reached a conclusion after an intense discussion in approving of Celltrion’s COVID-19 monoclonal antibody treatment Rekirona, conditionally authorized for use on Feb. 5. The Central Pharmaceutical Affairs Deliberation Committee was convened for a meeting on Jan. 2
